Festival of Biologics
Join us in-person in Basel, Switzerland for the Festival of Biologics where Just-Evotec Biologics will be presenting. You can find us any time at booth #27!
Who’s Attending
- Christelle Dagoneau, SVP Business Development at Just-Evotec Biologics
- Thierry Wurch, SVP Integrated Biologics Discovery at Just-Evotec Biologics
- Nigel Shipston, Senior Director Business Development at Just-Evotec Biologics
Connect with us via the official conference Swapcard app
Presentation | 2 November at 17:10 CET | Room: Singapore
Paradigm Shift in Biologics Manufacturing: Leveraging Continuous Manufacturing and AI/ML Based Technologies From Discovery to Market Supply
During this session, Christelle Dagoneau will present a unique platform concept which integrates the discovery, development, and manufacture of biologics in innovative and easily deployable production facilities called J.POD. She will particularly describe how the Just-Evotec Biologics cutting-edge AI/ML protein design technologies combined with industry-leading intensified continuous bioprocess can help de-risk and accelerate biotherapeutics development from lead generation through to BLA while offering cost-effective and truly flexible clinical and commercial supply solutions.
Presented by Christelle Dagoneau, SVP Business Development at Just-Evotec Biologics
Presentation | 3 November at 17:00 CET | Room: Shanghai 1&2
Evotec’s Integrated Biologics Discovery and Development Platform to Strengthen Immunotherapy Research Programs
At Evotec, we discover, develop and manufacture novel medicines for hard-to-treat diseases through efficient partnerships with academia, biotechs and pharma. Our discovery efforts focus on data-driven precision medicine and early disease relevance to improve success rates in identifying best-in-class therapeutics.
To support immunotherapy research projects, we developed an integrated discovery platform ranging from target validation, antibody discovery and optimization, in vitro/in vivo pharmacology, PK, and toxicology to select the best clinical candidates. By applying both humanized mouse-derived hybridoma and phage display coupled to AI/ML-based optimization, antibodies are selected based on disease relevant, target related in vitro and in vivo models. Applications for the identification of immune-modulating molecules will be discussed.
Presented by Thierry Wurch, SVP Integrated Biologics Discovery at Just-Evotec Biologics
Poster | #84
Conversion of an Intensified Fed-Batch to an Integrated Continuous Bioprocess
Despite advances in upstream and downstream Integrated Continuous Bioprocessing (ICB) technologies, reducing manufacturing costs and process development costs continue to be a concern.
Conversion of a fed-batch (FB) or intensified fed-batch (IFB) process into a hybrid or end-to-end ICB process may be particularly challenging but manageable using key platform elements:
- High specific productivity cell lines
- Low-cost, concentrated perfusion media formulations
- An optimized and scalable cell-retention device
- The impact to product quality remains as a potential issue stemming from higher culture cell densities, longer culture durations, and differences in product residence times.
This work involved the rapid conversion of an IFB mAb process to a hybrid ICB process using the Just-Evotec Biologics platform, resulting in several key project accomplishments:
- Mitigation of upstream IFB challenges: Filter fouling due to higher culture cell densities and durations was addressed by controlling cell density and implementing continuous harvest (CH).
- Significant productivity increase: 5-fold increase in product mass per working volume compared to original FB process at the 500L manufacturing scale.
- Short development time: < 6 months from project start to cGMP batch completion.
- Minimal risk from changes in product quality: most attributes (HMW and rCE) and process impurities (HCP, DNA, and Pro-A) were comparable (minor differences in glycan distribution).
These results demonstrate that the rapid conversion of FB and IFB mAb processes to ICB can be met when implementing a robust ICB platform, thus supporting the biotherapeutic industry’s need to quickly adapt to changing clinical and business circumstances.
Presented by Nigel Shipston, Senior Director Business Development at Just-Evotec Biologics
Speakers
-
Christelle DagoneauSVP Business DevelopmentChristelle has over 20 years of international business development and marketing experience in the life sciences and biologics CDMO industry. In her current role as SVP Business Development, Christelle leads the global Business Development team, with a focus on shaping innovative business strategies, building a strong industry presence and establishing Just – Evotec Biologics as a global leader in the AI-driven discovery to continuous manufacturing space. Prior to joining Just – Evotec Biologics, Christelle held several senior Business Development roles at Catalent where she supported the growth of the biologics division in Europe and led the European Cell Therapy Business Development team. Christelle also served as Head of Marketing and Sales at PX’Therapeutics, a French biologics CDMO and brings in an expert knowledge of the biotherapeutics and biosimilars markets, a passion for building strategic partnerships as well as strong Business Development culture and best practices.
Christelle received her Ph.D. in Organic Chemistry from the University of Grenoble, France and also holds a master in Technology & Business Management.
-
Nigel ShipstonSenior Director, Business DevelopmentNigel is responsible for Biologics Business Development activities in the UK and Europe. Prior to joining Evotec in 2021, Nigel spent 14 years at FUJIFILM Diosynth Biotechnologies as Director of Technical Marketing, Director of Program Design and Senior Technical Project Leader, supporting expansion of the business in Europe, USA and APAC. and has also served as Head of Process Development at Angel Biotechnology and has previously held Operations Manager and Senior Scientist positions at Oxford GlycoSciences and Abbott Laboratories. He has 30 years’ experience in the biotechnology industry and has been responsible for leading process development and manufacturing teams involved in the expression, purification and analysis of many commercially relevant recombinant protein biopharmaceuticals (biologics) and enzyme products.
Nigel received his BSc and Associateship of the Royal College of Science degrees from Imperial College of Science and Technology, London, UK and a PhD in biochemistry from the University of Kent, UK. -
Thierry WurchSVP Integrated Biologics DiscoveryThierry joined Evotec in May 2022 as SVP Integrated Biologics Discovery. He has more than 22 years of expertise in the antibody R&D space primarily in Oncology and immune-oncology. Thierry held positions of growing strategic importance from head of an antibody discovery and engineering department (Pierre Fabre, 2003-2011), head of immunotherapy discovery research activities (Servier, 2011-2017) then moving to BD-oriented activities and heading external innovation for Oncology (Servier, 2017-2020 and Ipsen 2020-2022). Thierry is also Chairman of the antibody sub-committee at NC-IUPHAR, member of the Editorial board of mAbs Journal and Distinguished Advisor of The Antibody Society.